Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul;35(7):1128-1133.
doi: 10.1002/mds.28030. Epub 2020 Mar 27.

Biofluid Biomarkers in Parkinson's Disease: Clarity Amid Controversy

Sophia R L Vieira  1 , Marco Toffoli  1 , Philip Campbell  1 , Anthony H V Schapira  1
Affiliations

Biofluid Biomarkers in Parkinson's Disease: Clarity Amid Controversy

Sophia R L Vieira et al. Mov Disord. 2020 Jul.
No abstract available

Keywords: Parkinson's disease; alpha-synuclein; biomarker; blood; cerebrospinal fluid; glucocerebrosidase; prodrome.

PubMed Disclaimer

References

    1. Elkouzi A, Vedam-Mai V, Eisinger RS, Okun MS. Emerging therapies in Parkinson disease - repurposed drugs and new approaches. Nat Rev Neurol 2019;15(4):204-223.
    1. Chen-Plotkin AS, Albin R, Alcalay R, et al. Finding useful biomarkers for Parkinson's disease. Sci Transl Med 2018;10(454):eaam6003.
    1. Sharma S, Moon CS, Khogali A, et al. Biomarkers in Parkinson's disease (recent update). Neurochem Int 2013;63(3):201-229.
    1. Gao L, Tang H, Nie K, et al. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis. Int J Neurosci 2015;125(9):645-654.
    1. Eusebi P, Giannandrea D, Biscetti L, et al. Diagnostic utility of cerebrospinal fluid alpha-synuclein in Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2017;32(10):1389-1400.

MeSH terms

LinkOut - more resources